<DOC>
	<DOC>NCT02756858</DOC>
	<brief_summary>This open label extension study is designed to provide continued access to ANAVEX 2-73 for eligible subjects with mild to moderate Alzheimer's Disease who have previously participated in the Anavex sponsored study ANAVEX2-73-002.</brief_summary>
	<brief_title>An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Previous exposure to ANAVEX273 via participation in Phase 2a Study of ANAVEX273 AdaptiveTrialDesign With Repeated Doses, MTD Finding, Pharmacodynamic and Bioavailability Evaluation in Patients With Mild to Moderate Alzheimer's Disease With a 12Month Open Label FollowUp Period (ANAVEX273002) Have not previously participated Phase 2a Study of ANAVEX273 AdaptiveTrialDesign With Repeated Doses, MTD Finding, Pharmacodynamic and Bioavailability Evaluation in Patients With Mild to Moderate Alzheimer's Disease With a 12Month Open Label FollowUp Period (ANAVEX273002)</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>